Posted in M&A / Deals BMS makes a Beeline, bringing 5 assets to biotech’s $300M precision immunology debut April 15, 2026 BioSpace Leading Beeline Medicines’ pipeline is afimetoran, which is in Phase 2 development for systemic lupus erythematosus with data expected later this year. M&A / DealsImmunology & InflammationRead full story